EP3601565A4 - Mir-92-inhibitoren zur behandlung von herzinsuffizienz - Google Patents

Mir-92-inhibitoren zur behandlung von herzinsuffizienz Download PDF

Info

Publication number
EP3601565A4
EP3601565A4 EP18777343.7A EP18777343A EP3601565A4 EP 3601565 A4 EP3601565 A4 EP 3601565A4 EP 18777343 A EP18777343 A EP 18777343A EP 3601565 A4 EP3601565 A4 EP 3601565A4
Authority
EP
European Patent Office
Prior art keywords
mir
inhibitors
treatment
heart failure
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18777343.7A
Other languages
English (en)
French (fr)
Other versions
EP3601565A1 (de
Inventor
Rabea Hinkel
Christian Kupatt
Stefanie Dimmeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viridian Therapeutics Inc
Original Assignee
Miragen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miragen Therapeutics Inc filed Critical Miragen Therapeutics Inc
Publication of EP3601565A1 publication Critical patent/EP3601565A1/de
Publication of EP3601565A4 publication Critical patent/EP3601565A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18777343.7A 2017-03-25 2018-03-23 Mir-92-inhibitoren zur behandlung von herzinsuffizienz Withdrawn EP3601565A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476780P 2017-03-25 2017-03-25
US201762477385P 2017-03-27 2017-03-27
PCT/US2018/024167 WO2018183127A1 (en) 2017-03-25 2018-03-23 Mir-92 inhibitors for treatment of heart failure

Publications (2)

Publication Number Publication Date
EP3601565A1 EP3601565A1 (de) 2020-02-05
EP3601565A4 true EP3601565A4 (de) 2021-01-06

Family

ID=63676655

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18777343.7A Withdrawn EP3601565A4 (de) 2017-03-25 2018-03-23 Mir-92-inhibitoren zur behandlung von herzinsuffizienz

Country Status (2)

Country Link
EP (1) EP3601565A4 (de)
WO (1) WO2018183127A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201791644A1 (ru) 2015-01-20 2018-01-31 Мираджен Терапьютикс, Инк. Ингибиторы mir-92 и их применение
EP4269586A1 (de) 2022-04-29 2023-11-01 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Targeting von mikro-rna zur behandlung von herzversagen mit konservierter ejektionsfraktion (hfpef)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115103A1 (en) * 2013-01-24 2014-07-31 Pierre Fabre Medicament S.A.S. Composition comprising an encapsulated antagomir

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086348A1 (en) * 2009-02-19 2011-04-14 The Cleveland Clinic Foundation Method for assessing heart disease
CN102481310A (zh) * 2009-05-20 2012-05-30 得克萨斯系统大学董事会 牵涉心肌梗死后重塑和心力衰竭的微小rna的鉴定
CN104685056A (zh) * 2012-06-21 2015-06-03 米拉根医疗股份有限公司 包含锁核酸基序的基于寡核苷酸的抑制剂
WO2015066611A2 (en) * 2013-11-01 2015-05-07 The Trustees Of Columbia University In The City Of New York Microrna profiles in heart failure: methods and systems for detection and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115103A1 (en) * 2013-01-24 2014-07-31 Pierre Fabre Medicament S.A.S. Composition comprising an encapsulated antagomir

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FUJITA MASANORI ET AL: "Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin a5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium", CIRCULATION, vol. 124, no. 21, Suppl. S, November 2011 (2011-11-01), & SCIENTIFIC SESSIONS OF THE AMERICAN-HEART-ASSOCIATION/RESUSCITATION SCIENCE SYMPOSIUM; ORLANDO, FL, USA; NOVEMBER 12 -16, 2011, pages A12590, XP002800953 *
R. HINKEL ET AL: "Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model", CIRCULATION, vol. 128, no. 10, 3 September 2013 (2013-09-03), US, pages 1066 - 1075, XP055375248, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.113.001904 *
See also references of WO2018183127A1 *
XINYU LIU ET AL: "Role of microRNAs in the pathogenesis of diabetic cardiomyopathy", BIOMEDICAL REPORTS MAY 2014 SPANDIDOS PUBLICATIONS GBR, vol. 6, no. 2, 12 January 2017 (2017-01-12), Greece, pages 140 - 145, XP055749498, ISSN: 2049-9434, DOI: 10.3892/br.2017.841 *

Also Published As

Publication number Publication date
EP3601565A1 (de) 2020-02-05
WO2018183127A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
EP3313325A4 (de) Implantierbare gerüste zur behandlung von sinusitis
EP3426250A4 (de) Behandlungsverfahren
EP3256218A4 (de) Kdm1a-hemmer zur behandlung von krankheiten
EP3261713A4 (de) Blutpumpe zur behandlung von bradykardie
EP3204009A4 (de) Hemmer der heparansulfatbiosynthese zur behandlung von krankheiten
EP3157534A4 (de) Acetylcholinesterasehemmer zur behandlung von dermatologischen zuständen
PT3297628T (pt) Azasetron para uso no tratamento de perda auditiva
EP3684342A4 (de) Behandlungsverfahren
EP3285767B8 (de) Behandlung von schmerzen
EP3490545A4 (de) Verfahren zur medizinischen behandlung mit sur1-trpm4-kanalinhibitoren
EP3256137A4 (de) Verfahren zur behandlung von herzversagen
IL250662B (en) Tissue protection devices for the treatment of heart failure and other conditions
EP3612133A4 (de) Implantierbare gerüste zur behandlung von sinusitis
EP3601565A4 (de) Mir-92-inhibitoren zur behandlung von herzinsuffizienz
EP3490547A4 (de) Verfahren zur behandlung
EP3259346A4 (de) P63-inaktivierung zur behandlung von herzinsuffizienz
EP3481399A4 (de) Verfahren zur behandlung von herzinsuffizienz
IL275273A (en) An improved compound for the treatment of heart failure
EP3271017A4 (de) Behandlung von hauterkrankungen
EP3612178A4 (de) Vasodilatatoren zur behandlung von herzinsuffizienz
EP3890780A4 (de) Verfahren zur behandlung
EP3727376A4 (de) Verfahren zur behandlung von hypertriglyceridämie
PT3724336T (pt) Composto melhorado para tratamento de insuficiência cardíaca
AU2017904855A0 (en) Method of treatment
AU2017903829A0 (en) Method of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201207

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101ALI20201130BHEP

Ipc: C12N 15/11 20060101AFI20201130BHEP

Ipc: A61K 31/712 20060101ALI20201130BHEP

Ipc: A61P 9/10 20060101ALN20201130BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210722